I strongly believe in leronlimab's potential with respect to HIV and cancer. I worked for in blood banking at the height of the AIDS crisis in the Eighties. The fastest way to get these indications fully funded is from potential profits from Covid and, potentially a higher price for stock if there needs to be an offering. Both, at this point, are Covid driven.

I disagree that any useful number published by a company creates distractions. Truthful numbers shed light. Company clarity let's you understand what you own, as well as the potential of what you own.